Publications by authors named "Gerty Schreibelt"

Claim this Profile
N
NEOadjuvant Dendritic cell therapy added to first line standard of care in advanced epithelial Ovarian Cancer (NEODOC): protocol of a first-in-human, exploratory, single-centre phase I/II trial in the Netherlands.
Bouke Koeneman, Gerty Schreibelt, Tjitske Duiveman-de Boer, Kevin Bos, Tom van Oorschot

BMJ Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines.
Agathe Carrier, Paolo Manghi, Carolina Alves Costa Silva, Imran Lahmar, Deborah Suissa, Gerty Schreibelt

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling mutagenic processes influencing the tumor mutational patterns of individuals with constitutional mismatch repair deficiency.
Dilys D Weijers, Snežana Hinić, Emma Kroeze, Mark Aj Gorris, Gerty Schreibelt

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of TOLERANT: phase I/II safety assessment of intranodal administration of HSP70/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis.
Arie Jan Stoppelenburg, Gerty Schreibelt, Bouke Koeneman, Paco Welsing, Evert-Jan Breman

BMJ Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
Gerty Schreibelt, Tjitske Duiveman-de Boer, Jeanette M Pots, Tom G M van Oorschot, Annemiek J de Boer

Methods Cell Biol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial.
Bouke J Koeneman, Gerty Schreibelt, Mark A J Gorris, Simone Hins-de Bree, Harm Westdorp

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.
Carolina Alves Costa Silva, Gianmarco Piccinno, Déborah Suissa, Mélanie Bourgin, Gerty Schreibelt

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Kalijn F Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W van Willigen, Simone Hins-de Bree

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for mouse and human DC generation.
Manfred B Lutz, Shafaqat Ali, Cindy Audiger, Stella E Autenrieth, Luciana Berod, Gerty Schreibelt

Eur J Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Dendritic Cell Subset Isolation by Magnetic Bead Sorting: A Protocol to Efficiently Obtain Pure Populations.
Georgina Flórez-Grau, Jorge Cuenca Escalona, Helena Lacasta-Mambo, Daphne Roelofs, Johanna Bödder, Gerty Schreibelt

Bio Protoc· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological responses to adjuvant vaccination with combined CD1c myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Martine Bloemendal, Kalijn F Bol, Steve Boudewijns, Mark A J Gorris, Johannes H W de Wilt, Gerty Schreibelt

Oncoimmunology· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Gerty Schreibelt

Oncoimmunology· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.
Simone P Sittig, Jasper J P van Beek, Georgina Flórez-Grau, Jorieke Weiden, Sonja I Buschow, Gerty Schreibelt

Eur J Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Johanna Bödder, Tasmin Zahan, Rianne van Slooten, Gerty Schreibelt, I Jolanda M de Vries

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome.
Asima Abidi, Mark A J Gorris, Evan Brennan, Marjolijn C J Jongmans, Dilys D Weijers, Gerty Schreibelt

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer.
Harm Westdorp, Jeroen H A Creemers, Inge M van Oort, Niven Mehra, Simone M Hins-de Bree, Gerty Schreibelt

Front Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Renske M T Ten Ham, Anke M Hövels, Jarno Hoekman, Geert W J Frederix, Hubert G M Leufkens, Gerty Schreibelt

Cytotherapy· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Steve Boudewijns, Martine Bloemendal, Nienke de Haas, Harm Westdorp, Kalijn F Bol, Gerty Schreibelt

Cancer Immunol Immunother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.
Wouter W van Willigen, Martine Bloemendal, Marye J Boers-Sonderen, Jan Willem B de Groot, Rutger H T Koornstra, Gerty Schreibelt

Oncoimmunology· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.
Jasper J P van Beek, Georgina Flórez-Grau, Mark A J Gorris, Till S M Mathan, Gerty Schreibelt

Cell Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Harm Westdorp, Jeroen H A Creemers, Inge M van Oort, Gerty Schreibelt, Mark A J Gorris

J Immunother Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.
Wouter W van Willigen, Martine Bloemendal, Winald R Gerritsen, Gerty Schreibelt, I Jolanda M de Vries

Front Immunol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Kalijn F Bol, Gerty Schreibelt, Katrin Rabold, Stefanie K Wculek, Julia Katharina Schwarze

J Immunother Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.
Marc Eissing, Lise Ripken, Gerty Schreibelt, Harm Westdorp, Marjolijn Ligtenberg

Transl Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
Thomas J van Ee, Heleen H Van Acker, Tom G van Oorschot, Viggo F Van Tendeloo, Evelien L Smits, Gerty Schreibelt

Vaccines (Basel)· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis